Kim A. Reiss, MD, on HER2-Overexpressing Solid Tumors: First-in-Human Study of Anti-HER2 CAR Macrophages

November 30, 2021 By The ASCO Post Staff

Kim A. Reiss, MD, of the University of Pennsylvania, discusses results of a phase I trial of a CAR-M engineered macrophage cancer therapy, known as CT-0508, for patients with solid tumors that overexpress HER2. CAR-M, designed to exploit the natural role of macrophages to initiate an antitumor response, is currently under study at multiple clinical sites (Abstract 951).

Related Content